CD34 and Miyoshi myopathy: Our finding in the MM cohort, that all the patients achieved the target (≥ 2 × 106/kg) while the rate of plerixafor administration was < 60%, indicates that pegfilgrastim alone can mobilize and allow the collection of sufficient HSCs from peripheral blood if patients have sufficient CD34-positive cells in peripheral blood before apheresis.